Answers are grounded in this paper and cite their sources.
Primary adnexal carcinomas are rare, heterogeneous malignancies with limited evidence guiding the management of locally advanced disease, including the use of checkpoint inhibition. We report a 67-year-old man with a poorly differentiated cutaneous adnexal carcinoma, not otherwise specified (NOS), of the palm who received off-label neoadjuvant cemiplimab since upfront surgical resection would result in significant functional morbidity. After approximately 8 months of therapy, there was clinical and radiographic response as confirmed with tumor reduction from 5.2 x 3.8 cm to 2.3 x 1.2 cm. Serial tumor-informed ctDNA measurements initially fell but then rose despite continued radiographic improvement. This led us to proceed with surgery, as the molecular data suggested we had likely achieved our maximum benefit. The surgery was an index ray amputation rather than the more extensive hand amputation that had been initially planned. Pathology revealed residual disease with multifocal lymphovascular invasion and a focally positive deep microscopic margin. Post-operation ctDNA became undetectable, and subsequent MRI showed no evidence of disease. However, long-term oncologic control after less extensive surgery with a microscopically positive margin remains unknown. This case highlights the potential utility of longitudinal ctDNA monitoring in guiding individualized management of rare malignancies. Neoadjuvant PD-1 blockade and use of ctDNA to inform timing of surgery in this setting remain investigational.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: